Lyrica 150mg Capsule contains Pregabalin, an anticonvulsant and neuropathic pain agent used primarily for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, and spinal cord injury. It is also indicated as adjunctive therapy for partial onset seizures in adults and for the treatment of generalized anxiety disorder. Pregabalin acts by binding to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, thereby modulating neurotransmitter release and reducing neuronal excitability. The 150mg dosage is typically prescribed based on clinical response and tolerability, with dose adjustments made to optimize therapeutic outcomes while minimizing adverse effects. Common side effects include dizziness, somnolence, dry mouth, edema, blurred vision, and weight gain. Caution is advised in patients with renal impairment, as dose modification may be necessary. Lyrica should be used under medical supervision, with careful consideration of potential drug interactions and contraindications. Abrupt discontinuation is not recommended due to the risk of withdrawal symptoms. Patients should be monitored regularly to assess efficacy and safety during treatment. This medication is contraindicated in individuals with known hypersensitivity to pregabalin or any of its excipients.